Indobufen
Phase 3Small molecule
PfizerIndobufen is one of 60 small molecule programs targeting Acute Coronary Syndrome. It is currently in Phase 3.
2
Indications
5
Total Trials
1
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
53 competitors in Acute Coronary Syndrome
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Brilinta
AstraZenecaApproved
Crestor
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Colcrys
Jazz PharmaceuticalsApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Leqvio
NovartisApproved
Lescol
NovartisApproved
Praluent
RegeneronApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Coronary Syndrome1 trial
Atrial Fibrillation1 trial
Anticoagulant1 trial
Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent
Unknown status·—·Phase 1·NCT01232023·12 enrolled
Ischemic stroke1 trial
INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE
Completed·—·Phase 4·NCT03871517·5,438 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Indobufen. EMBL-EBI & Wellcome Sanger Institute.
- [4]